Physician

Ahmad Shah Barakzoy, M.D.

According to 2025 Medicare claims, Ahmad Barakzoy, M.D. (NPI: 1245335470) practices nephrology in the Jacksonville, FL market, with the plurality of this provider's patient population coming from Clay, FL. This provider's primary affiliated billing organization is AHMAD S BARAKZOY MD LLC (NPI: 1760795413; TIN: 27-3030686) and primary practice location at 32073-9998.

Barakzoy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 356 traditional Medicare patients, billed 2,433 HCPCS/CPT codes, and received $243,750 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 690 prescription claims across 150 beneficiaries totaling $236,620 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 78 claims. Open Payments data shows 4 records totaling $84. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $373,164 to $243,750. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $325,235 and ending at $236,620. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	556	4,229	$373,164
2016	518	4,254	$392,485
2017	491	3,753	$492,639
2018	546	3,915	$405,115
2019	565	4,241	$443,146
2020	505	3,915	$392,810
2021	440	3,933	$403,822
2022	382	2,909	$318,509
2023	362	2,611	$276,325
2024	356	2,433	$243,750

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	232	2,264	$325,235
2016	228	2,259	$465,874
2017	235	1,884	$344,876
2018	240	1,529	$200,797
2019	226	1,319	$191,050
2020	218	1,260	$322,838
2021	190	1,030	$265,025
2022	169	857	$408,120
2023	163	718	$432,611
2024	150	690	$236,620

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	48	$1,507
2023	N/R	35	$395
2024	N/R	78	$1,009

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	84	100	$134
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	51	51	$128
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	37	68	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	215	509	$68
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	99	1,237	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	58	2,400	$180,983
Lanthanum Carbonate	Lanthanum Carbonate	18	600	$13,355
Sevelamer Carbonate	Sevelamer Carbonate	73	3,570	$9,879
Calcitriol	Calcitriol	68	4,446	$1,632
Allopurinol	Allopurinol	69	5,520	$450

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	27	$461
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	13	$268
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$263
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	22	$16

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$84	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmad Shah Barakzoy, M.D.?

Tedicare shows public-source Medicare data for Ahmad Shah Barakzoy, M.D. (NPI 1245335470), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmad Shah Barakzoy, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ahmad Shah Barakzoy, M.D.?

Ahmad Shah Barakzoy, M.D. is linked to AHMAD S BARAKZOY MD LLC (billing NPI 1760795413) in the available physician profile data.

Does Ahmad Shah Barakzoy, M.D. have Open Payments data?

Ahmad Shah Barakzoy, M.D. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.